decitabine/ tetrahydrouridine (EPI01) / Novo Nordisk, EpiDestiny  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
decitabine/ tetrahydrouridine (EPI01) / EpiDestiny, Novo Nordisk
2020-003485-39: Research study investigating how well NDec works in people with sickle cell disease

Ongoing
2
84
Europe
Decitabine/Terahydrouridine A 5/250mg, Capsule, Film-coated tablet, Siklos
Novo Nordisk A/S, Novo Nordisk A/S
Sickle cell disease, Chronic, inherited blood disorder that impacts haemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
ASCENT1, NCT05405114 / 2020-003485-39: Research Study Investigating How Well NDec Works in People With Sickle Cell Disease

Recruiting
2
84
Europe, Canada, US, RoW
NDec - oral decitabine-tetrahydrouridine, HU - Hydroxyurea, Placebo
Novo Nordisk A/S, Novo Nordisk A/S
Sickle Cell Disease
10/24
07/25

Download Options